Pinus Sylvestris Pollen

Dosage for Pinus Sylvestris Pollen is highly individualized and follows a two-phase protocol: the Build-up (Escalation) Phase and the Maintenance Phase.

Build-up Phase

In this initial phase, the patient receives injections once or twice a week. The starting dose is extremely low, often 0.05 mL of a 1:100,000 w/v or 1:10,000 w/v dilution. The dose is gradually increased with each subsequent injection (e.g., 0.1 mL, 0.2 mL, 0.4 mL) until the target maintenance dose is reached. This phase typically lasts 3 to 6 months.

Maintenance Phase

Once the maintenance dose is reached (often 0.5 mL of a 1:100 or 1:10 w/v solution), the frequency of injections is decreased to once every 2 to 4 weeks. This phase is usually continued for 3 to 5 years to ensure long-lasting immunity.

Pinus Sylvestris Pollen is generally approved for use in children, typically starting at age 5. The dosing schedule for children is similar to that of adults, though the physician may choose to increase the dose more conservatively. Children must be able to communicate symptoms of a systemic reaction and remain still for the injection and the subsequent 30-minute observation period.

Renal Impairment

No specific dosage adjustments are required for patients with renal impairment, as the extract is not cleared by the kidneys in a manner that would lead to toxicity.

Hepatic Impairment

No dosage adjustments are necessary for patients with hepatic impairment.

Elderly Patients

Caution is advised in elderly patients, particularly those with underlying cardiovascular disease. The risk of being unable to tolerate a systemic reaction or the epinephrine used to treat such a reaction must be weighed against the benefits of immunotherapy.

Pinus Sylvestris Pollen allergenic extract is administered via subcutaneous injection, usually in the posterior aspect of the upper arm.

• Preparation: The vial should be inspected for particulate matter or discoloration before use. The skin site should be cleaned with an alcohol swab.
• Administration: The injection is given subcutaneously (not intramuscularly or intravenously). The plunger should be slightly withdrawn before injecting to ensure a blood vessel has not been entered.
• Post-Injection: The patient must remain in the doctor's office for at least 30 minutes following the injection. This is the period when life-threatening anaphylaxis is most likely to occur.
• Storage: Vials must be stored in a refrigerator at 2°C to 8°C (36°F to 46°F). Do not freeze.

If a dose is missed during the build-up phase, the next dose may need to be reduced or the previous dose repeated, depending on how much time has passed. If a dose is missed during the maintenance phase, the physician will determine if a temporary dose reduction is necessary to prevent a reaction when resuming treatment.

An 'overdose' in the context of allergenic extracts usually refers to an injection of a concentration higher than the patient's current tolerance level. Signs of overdose include:

• Rapid onset of hives (urticaria)
• Swelling of the throat or tongue
• Difficulty breathing or wheezing
• Drop in blood pressure (fainting or dizziness)

Emergency measures include the immediate administration of epinephrine (0.3mg to 0.5mg IM) and supportive care for anaphylaxis.

> Important: Follow your healthcare provider's dosing instructions. Do not adjust your dose without medical guidance.

Local reactions at the site of injection are the most frequent side effects of Pinus Sylvestris Pollen immunotherapy. These are generally not dangerous but can be uncomfortable.

• Local Swelling (Wheal): A raised, red bump at the injection site that may appear within minutes.
• Erythema (Redness): Redness surrounding the injection site that can spread several centimeters.
• Pruritus (Itching): Intense itching at the injection site, which typically resolves within a few hours.
• Induration: A hardening of the tissue at the site of the injection, which may last for 24 to 48 hours.

• Fatigue: Some patients report feeling tired or 'washed out' for several hours after an injection.
• Mild Nasal Congestion: A slight 'flare' of allergy symptoms shortly after treatment.
• Headache: Mild tension-type headaches have been reported following escalation doses.

• Generalized Urticaria: Hives appearing on parts of the body far from the injection site.
• Angioedema: Swelling of the deeper layers of the skin, often around the eyes or lips.
• Persistent Cough: A dry cough that may indicate mild bronchial irritation.

> Warning: Stop taking Pinus Sylvestris Pollen and call your doctor immediately if you experience any of these symptoms of anaphylaxis.

• Anaphylaxis: This is a life-threatening systemic allergic reaction. It can involve multiple organ systems and progresses rapidly. Symptoms include a feeling of doom, rapid pulse, and low blood pressure.
• Bronchospasm: Severe wheezing, chest tightness, or difficulty breathing, particularly in patients with a history of asthma.
• Laryngeal Edema: Swelling of the throat that makes it difficult to swallow or speak, often described as a 'lump in the throat.'
• Hypotension: A sudden drop in blood pressure that can lead to fainting, dizziness, or loss of consciousness.
• Cyanosis: A bluish tint to the lips or fingernails, indicating a lack of oxygen.

There are no known long-term 'toxic' effects of Pinus Sylvestris Pollen, as it is a natural protein extract. However, long-term use can lead to:

• Persistent Local Nodules: Small, hard bumps under the skin at frequent injection sites.
• Immune Complex Formation: While theoretically possible, systemic vasculitis or other immune complex diseases are extremely rare in patients receiving standard immunotherapy doses.

Pinus Sylvestris Pollen extracts carry a standard FDA-mandated warning for allergenic extracts:

WARNING: RISK OF SEVERE ALLERGIC REACTIONS

Allergenic extracts can cause severe life-threatening systemic reactions, including anaphylaxis. Patients must be observed for at least 30 minutes in a medical facility after every injection. Immunotherapy should only be administered by physicians who are experienced in the treatment of anaphylaxis and have the necessary equipment (epinephrine, oxygen, airway management) available.

Report any unusual symptoms to your healthcare provider.

Pinus Sylvestris Pollen is intended for use only by patients with a confirmed diagnosis of pine pollen allergy. It is not a general treatment for all types of hay fever. Patients must be informed of the risks of immunotherapy and must be willing to comply with the 30-minute observation period after each dose.

No FDA black box warnings specifically for Pinus Sylvestris Pollen beyond the class-wide warning for all allergenic extracts regarding the risk of anaphylaxis. The primary danger is a systemic allergic reaction that can occur even in patients who have previously tolerated the same dose without issue.

• Allergic Reactions / Anaphylaxis Risk: The risk is highest during the build-up phase and when switching to a new vial of extract, as potency can vary between lots.
• Asthma Status: Patients with unstable or poorly controlled asthma are at a significantly higher risk for a fatal reaction to immunotherapy. Injections should be withheld if the patient is experiencing an asthma flare-up or if their Peak Expiratory Flow (PEF) is significantly below their personal best.
• Beta-Blocker Use: Patients taking beta-blockers (e.g., metoprolol, propranolol) may be resistant to the effects of epinephrine, making a systemic reaction much harder to treat. This is often considered a relative or absolute contraindication.
• Concurrent Illness: Injections should be postponed if the patient has an acute infection, fever, or is otherwise feeling unwell, as this may lower the threshold for a systemic reaction.

• Observation Period: A mandatory 30-minute wait in the clinic after every injection.
• Lung Function: For asthmatic patients, a pre-injection peak flow meter reading may be required.
• Skin Inspection: The injection site should be checked for large local reactions before the patient leaves the clinic.
• Vial Potency: Healthcare providers must carefully check the concentration and expiration date of the vial before every administration.

Most patients can drive after the 30-minute observation period. However, if a patient experiences significant fatigue or a mild systemic reaction, they should avoid driving until symptoms have fully resolved.

Alcohol consumption should be avoided for several hours before and after an injection. Alcohol can increase blood flow to the skin and potentially speed up the absorption of the allergen, increasing the risk of a reaction.

Immunotherapy can be discontinued if the patient has completed 3 to 5 years of treatment and is symptom-free. It should be discontinued immediately if the patient experiences a life-threatening reaction that cannot be managed or if they develop a contraindication like severe cardiovascular disease.

> Important: Discuss all your medical conditions with your healthcare provider before starting Pinus Sylvestris Pollen.

• Beta-Adrenergic Blockers (Beta-Blockers): This includes both systemic and ophthalmic (eye drop) forms. Beta-blockers can increase the severity of an allergic reaction and, more importantly, block the life-saving effects of epinephrine if anaphylaxis occurs. This combination is generally avoided unless the benefit clearly outweighs the risk.

• ACE Inhibitors: Some studies suggest that patients taking ACE inhibitors (e.g., lisinopril) may be at an increased risk for more severe systemic reactions to immunotherapy, possibly due to interference with the breakdown of bradykinin.
• MAO Inhibitors (MAOIs): These drugs can potentiate the effects of sympathomimetics used to treat reactions, potentially leading to hypertensive crises if epinephrine is administered.

• Antihistamines: While not dangerous, antihistamines can mask the early signs of a systemic reaction (like itching or hives), potentially delaying the diagnosis of anaphylaxis. They also interfere with diagnostic skin testing and must be stopped several days prior to testing.
• Tricyclic Antidepressants: Similar to MAOIs, these can affect the cardiovascular response to epinephrine.

There are no direct food interactions with Pinus Sylvestris Pollen. However, patients should avoid heavy meals or vigorous exercise for 2 hours after an injection, as these can increase systemic circulation and the risk of a reaction.

• St. John's Wort: May theoretically affect the metabolism of medications used to treat reactions, though clinical data is lacking.
• Ephedra/Ma Huang: Could increase the risk of cardiovascular side effects if a patient requires epinephrine.

• Skin Testing: Pinus Sylvestris Pollen extract will obviously cause a positive result in a skin test for pine allergy.
• Total IgE: Immunotherapy may cause a transient rise in total serum IgE levels before they eventually decline.
• Specific IgG4: Clinical labs may show an increase in pine-specific IgG4, which is a marker of successful desensitization.

For each major interaction, the mechanism is usually pharmacodynamic (affecting the body's response to the drug or the rescue medication) rather than pharmacokinetic (affecting the drug's levels). Management strategies involve either discontinuing the interacting drug or proceeding with extreme caution and lower doses of the extract.

> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking.

• Severe, Uncontrolled Asthma: Patients with a Forced Expiratory Volume in 1 second (FEV1) persistently below 70% of predicted values should not receive immunotherapy, as they are at high risk for fatal bronchospasm.
• History of Severe Anaphylaxis to Immunotherapy: If a patient has previously had a near-fatal reaction to pine pollen extract, the risk of continuing usually outweighs any potential benefit.
• Active Malignancy: Immunotherapy is generally avoided in patients with active cancer, as the immune system is already compromised or under significant stress.
• Severe Immunodeficiency: Patients with primary or secondary immunodeficiencies may not be able to mount the appropriate regulatory immune response.

• Cardiovascular Disease: Patients with unstable angina or recent myocardial infarction (heart attack) may not be able to tolerate the stress of a systemic reaction or the epinephrine used to treat it.
• Beta-Blocker Therapy: As noted in the interactions section, this makes treating anaphylaxis significantly more difficult.
• Pregnancy: While not a reason to stop maintenance therapy, immunotherapy is generally not started during pregnancy due to the risk of anaphylaxis-induced fetal hypoxia.
• Eosinophilic Esophagitis (EoE): There is some evidence that pollen immunotherapy may exacerbate or trigger EoE in susceptible individuals.

Patients allergic to Pinus Sylvestris Pollen may show cross-reactivity with other members of the Pinaceae family, including:

• Pinus strobus (White Pine)
• Pinus nigra (Austrian Pine)
• Picea species (Spruce)
• Abies species (Fir)

> Important: Your healthcare provider will evaluate your complete medical history before prescribing Pinus Sylvestris Pollen.

Pinus Sylvestris Pollen is classified as Pregnancy Category C. This means that animal reproduction studies have not been conducted, and it is not known whether it can cause fetal harm.

• Risk-Benefit: Healthcare providers generally do not initiate immunotherapy during pregnancy because the risk of a systemic reaction (anaphylaxis) could lead to a sudden drop in blood pressure and oxygen delivery to the fetus (fetal hypoxia).
• Maintenance: If a patient is already on a stable maintenance dose and becomes pregnant, the treatment is often continued, as the risk of a reaction is much lower than during the build-up phase.

It is not known whether the components of Pinus Sylvestris Pollen extract are excreted in human milk. However, since these are large proteins that are processed locally and immunologically, it is highly unlikely that they would reach the infant in significant amounts through breastfeeding. Most experts consider immunotherapy to be compatible with breastfeeding.

• Approved Age: Clinical use is generally restricted to children 5 years of age and older.
• Considerations: Children under 5 may have difficulty communicating the early symptoms of a reaction. Furthermore, the psychological impact of frequent injections must be considered. Studies have shown that early immunotherapy in children may prevent the development of new sensitivities (the 'allergic march') and reduce the risk of developing asthma.

• Cardiovascular Risk: Patients over 65 are more likely to have underlying heart disease, which increases the risk of complications if a systemic reaction occurs.
• Polypharmacy: Elderly patients are more likely to be taking beta-blockers or ACE inhibitors, which complicate the safety profile of immunotherapy.
• Clearance: While renal/hepatic clearance is not an issue, the overall robustness of the immune response may be diminished in the elderly.

There are no specific guidelines for Pinus Sylvestris Pollen in patients with renal impairment. Because the extract consists of proteins that are metabolized by the immune system, kidney function does not affect the safety or efficacy of the treatment.

Similarly, liver function does not play a role in the metabolism of allergenic extracts. No dosage adjustments are needed for patients with cirrhosis or other liver diseases.

> Important: Special populations require individualized medical assessment.

Pinus Sylvestris Pollen extract acts as an immunomodulator. Its primary molecular target is the T-cell receptor on CD4+ T-helper cells. By presenting pine pollen allergens in a controlled, escalating fashion, the extract induces 'peripheral tolerance.'

1. 1T-Reg Induction: It stimulates the production of regulatory T-cells (Tregs) that secrete IL-10.
2. 2B-Cell Switching: It induces B-lymphocytes to switch from producing IgE (the allergy antibody) to IgG4 (the blocking antibody).
3. 3Mast Cell Desensitization: Over time, the threshold for mast cell and basophil activation is increased, meaning more pollen is required to trigger a reaction.

• Onset of Effect: The clinical benefits of Pinus Sylvestris Pollen are not immediate. Most patients begin to notice a reduction in symptoms after 3 to 6 months of treatment, once the maintenance dose is approached.
• Duration of Effect: The goal of a 3-to-5-year course is to provide 'permanent' or long-lasting relief that persists for years after the injections are stopped.
• Tolerance: Unlike many drugs, tolerance to the side effects of the extract is a desired clinical outcome, allowing for higher, more effective doses.

| Parameter | Value |

|---|---|

| Bioavailability | N/A (Subcutaneous administration) |

| Protein Binding | N/A (Processed by immune cells) |

| Half-life | Days (Immunological effect lasts weeks) |

| Tmax | 30-60 minutes (for systemic absorption) |

| Metabolism | Proteolysis by Antigen Presenting Cells |

| Excretion | Cellular degradation |

• Composition: A complex aqueous extract containing proteins (profilins, polcalcins), carbohydrates, and lipids.
• Solubility: Highly soluble in water or saline-based buffers.
• Molecular Weight: Ranges from 10 kDa to over 70 kDa for various allergenic proteins (e.g., Pin s 1).

Pinus Sylvestris Pollen is a member of the Allergenic Extracts therapeutic class. It is further sub-classified as a Non-Standardized Pollen Extract. Related medications include other tree pollen extracts like Oak, Birch, and Maple, though each is specific to the patient's sensitivity.